Since the introduction of recombinant DNA technology, significant advances have been made in the production and clinical use of recombinant human haematopoietic growth factors . These factor~are glycoprotein hormones that control the proliferation, differentiation and maturation of haematopoietic progenitor cells, and the subsequent functional activity of the mature cells . Three haematopoietic growth factors are currently approved for clinical use.Ul • granulocyte colony-stimulating factor (G-CSF)
• granulocyte-macrophage colony-stimulating factor (GM-CSF)
• erythropoietin.
Others, such as interleukin 3, stem cell factor and macrophage colony-stimulating factor have also been produced on a large scale and are currently undergoing clinical evaluation.l 2,3l Clinical use of the 2 commercially available colony-stimulating factors (CSFs) has had a remarkable impact on the treatment of patients with haematological and neoplastic conditions. For example, the use of these agents in patients undergoing myeloablative chemotherapy for neoplastic disease or after autologous and allogeneic bone marrow transplantation has led to significant improvements in haematological recovery.IU These clinical advances have associated cost implications.
Although these factors are relatively expensive, acquisition costs need to be balanced against clinical benefits in terms of improved treatment and reduced costs of care . The efficacy of G-CSF and GM-CSF in different clinical settings and the pharmacoeconomic implications of their use are currently subjects of considerable interest.
Functional and Proliferative Properties of G-CSF and GM-CSF and their Clinical Implications
G-CSF and GM-CSF act at different stages in the haematopoietic process in which peripheral blood cells are generated from pluripotent stem cells. G-CSF is a more specific and later-acting agent that predominantly stimulates myeloid progenitor cells of the granulocyte-monocyte lineage, leading to the proliferation of CFU-G (colonyforming units -granulocyte) and their development into mature neutrophils. G-CSF also affects mature neutrophil function, stimulating their release from bone marrow into the peripheral circulation, and increasing their chemotactic and phagocytic activity at sites of infection.Hvl GM-CSF, as its name implies, is a multilineage CSF that acts at several stages in the proliferation and differentiation of myeloid cell lines. By virtue of its action on several CFU progenitor cells, GM-CSF stimulates the production of neutrophils, eosinophils and Fox monocyte/macrophages.lvl In contrast to G-CSF, GM-CSF inhibits the migration of mature neutrophils.l"l but prolongs the half-life of circulating neutrophils.Rl Table I summarises the various forms of G-CSF and GM-CSF currently in clinical use and their functional and proliferative effects on haematopoiesis.
The clinical implications of these proliferative effects were quickly recognised. Severe neutropenia and the consequent increased risk of infection is a major problem associated with cancer chemotherapy and autologous bone marrow transplantation, and the CSFs offered a means of stimulating haematopoietic recovery. Moreover, disorders of bone marrow function, such as myelodysplasia, aplastic anaemia and idiopathic neutropenias, might respond to treatment with these factors . Mass production of G-CSF and GM-CSF ensued, and several recombinant forms of these 2 factors are now available, both glycosylated and nonglycosylated (table I) . The importance of glycosylation to the activity of CSFs has yet to be clearly defined.[2.8-12 1
Current Clinical Applications

Chemotherapy-Induced Neutropenia
G-CSF is currently used to prevent or reduce the severity of neutropenia and associated complica- Table I . Currently available forms of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) and their functional and proliferative effects on haematopoiesis G-CSF Prophylactic use of GM-CSF also reduces the duration of severe neutropenia in patients receiving standard chemotherapy for conditions such as non-Hodgkin's lymphoma, breast cancer and lymphoma. However, further studies are needed to determine whether this haematological response translates into a beneficial clinical response. Moreover, GM-CSF itself may induce fever and other adverse effects, so its therapeutic role in this setting is less clearJI3) At present, there is little clinical evidence to support the use of GM-CSF in this setting rather than G-CSFJI7]
Available forms
Le.nograstim: recombinant glycosylated human-identical G-CSF (rHuG-CSF) . Expressed in mammalian cells
High Dose Chemotherapy with Bone Marrow Transplantation
The tran splantation of haematopoietic stem cells is used to try to overcome se vere myelosuppression associated with high dose chemotherapy. However, there is a period of pancytopenia before full haematopoietic recovery, in which there is a high incidence of febrile episodes and a need for erythrocyte and platelet tran sfusion s.U''l G-CSF and GM-CSF are currently used to stimue Adls Interna tiona l li mited. A li rig hts reserved . GM-CSF has also been used to accelerate haematopoietic recovery in patients who have undergone autologous bone marrow transplantation. In patients with various haematological and nonhaematological malignancies, such as non-Hodgkin's lymphoma, Hodgkin's disease, brea st cancer and melanoma, clinical outcomes are similar to those achie ved using G-CSF. In some studies, GM -CSF has also been shown to accelerate platelet and monocyte recovery, resulting in some instances in a reduction in the requirement for platelet transfusion sJI ,6,13,1 8]Thus , both agents reduce morbidity associated with this procedure, although a reduction in overall mortality with one or other factor has yet to be demonstrated.P'll However, clinical experience internationally indicates that G-CSF is preferred, primarily because of its superior tolerability profile.
Potential Clinical Uses
The range of potential clinical uses of G-CSF and GM-CSF is rapidly evolving as knowledge of their pharmacological effects and clinical value accrues. Table II gives a summary of those areas for which reliable (albeit in some cases preliminary) clinical data exist. 
Adjunct to Cancer Chemotherapy in Patients with Nonmyeloid Malignancies
To date, patients with a variety of solid tumours (including breast cancer and urothelial cancer) and other nonmyeloid malignancies have been shown to benefit from prophylactic G-CSF treatment after standard dose chemotherapy. It is reasonable to assume that patients undergoing chemotherapy for other solid tumours might also gain from CSF therapy. Further clinical studies should allow us to better define the efficacy of using G-CSF support in each setting. In addition, G-CSF has shown potential in the treatment of established chemotherapy-induced neutropenic infection, and this warrants additional investigation.U''J It may be that certain subgroups of patients will respond better than others to this G-CSF 'rescue' therapy, and this remains to be determined.
The case for using GM-CSF in this setting is less clear. As described earlier, although GM-CSF has been shown to stimulate neutrophil recovery in patients with nonmyeloid malignancies receiving standard myelosuppressive chemotherapy, there is presently no evidence to suggest that GM-CSF offers any advantages over G-CSF in this situation, © Adi s International Limited . All rights reserved.
and clinical studies of this factor are concentrating on other, more appropriate uses of this agent.
Chemotherapy Dose Optimisation and Intensification
Data from a number of studies have suggested that one consequence of G-CSF or GM-CSF therapy in patients receiving myelosuppressive chemotherapy is that more patients are able to receive their planned chemotherapy on time and at full dose (dose optimisationj.lv-"l This is of considerable interest at present to clinicians, as haematological toxicity and resulting infections often delay the administration of the next cycle of chemotherapy and/or necessitate dosage reductions in the chemotherapeutic agents employed. The potential advantages in being able to optimise a chemotherapy regimen through the use of G-CSF are obvious. This effect has also led to investigations into the possibility of intensifying the chemotherapy dose administered in cancers that exhibit a dose-response phenomenon. This can be achieved either by using higher doses of the chemotherapeutic agents or by reducing the time between successive cycles (i.e. increasing the amount of drug ad-ministered per unit of time). Moderate degrees of dose intensification (2-to 3-fold increases) can often be achieved by either G-CSF or GM-CSF support in patients with breast cancer, urothelial cancer, small cell lung cancer and other nonmyeloid malignancies without the need for bone marrow transplantation or peripheral blood progenitor cell support)20-23) Further investigations should clarify the extent to which dose intensification can be achieved and tolerated in such patients, the relative benefits of using one or other of the CSFs and, most importantly, the effects of chemotherapy dose optimisation and intensification on patient survival.
Graft Failure Following Autologous or Allogeneic Bone Marrow Transplantation
G-CSF and GM-CSF have been used to enhance haematopoietic recovery in patients with graft failure after autologous or allogeneic bone marrow transplantation.[1,4,6) There had been concerns that CSFs might increase the incidence or severity of graft-versus-host disease or graft failure through the direct stimulation of T lymphocytes.Rtl However, studies to date show this concern to be unwarranted.U: 17, 18)
PBPC Mobilisation and Transplantation
The collection of circulating peripheral blood progenitor cells (PBPCs) has recently been used as an alternative to bone marrow harvest before autologous bone marrow cell transplantation, particularly in patients who have extensive damage to myeloid stem cells resulting from previous cytotoxic therapy. The subsequent reinfusion of PBPCs, either as an adjunct to bone marrow transplantation or alone, has been used to stimulate haematopoietic recovery after myeloablative chemotherapy. Some of the most exciting prospects for the CSFs include using them to mobilise or 'prime' PBPCs in patients before apheresis and to enhance the subsequent engraftment of PBPCs with or without bone marrow. In recent clinical trials, both G-CSF and GM-CSF have demonstrated considerable potential in these settings )6,24-26] A major advantage is a more rapid recovery of plate-lets. [27) In fact, in a large number of centres in Australia, Europe and the US, autologous PBPC mobilisation and transplantation with CSF support has already replaced autologous bone marrow transplantation. Furthermore, there is evidence that, with CSF support, fewer leukapheresis procedures are required to obtain a sufficient number of cells for reinfusion)25) Current clinical studies are aimed at determining at which stage or stages of PBPC mobilisation and transplantation the CSFs should be employed.
With the optimal use of CSFs it may be possible to harvest sufficient stem cells in a single leukapheresis to induce haematological recovery, rather than by the multiple aphereses presently usedJ20 -26] This achievement would have significant economic and clinical outcomes that could dramatically improve patient care.
In the allogeneic setting, there are uncertainties regarding the potential clinical use of G-CSF and GM-CSF to support the use of PBPC harvest and reinfusion. To date the role of PBPCs and G-CSF or GM-CSF support in allogeneic bone marrow transplantation has yet to be determined, and is currently the subject of clinical trials.
Haematological Malignancies
The use of CSFs in patients with disorders of myeloid function has been somewhat controversial, because these agents have been shown to stimulate the proliferation of malignant myeloid leukaemia cells in vitro)!] However, promising results have been obtained for both G-CSF and GM-CSF in the treatment of chemotherapy-induced neutropenia in patients with acute myeloid leukaemia undergoing intensive chemotherapy. Both agents have been reported to shorten the period of neutropenia after chemotherapy, with an associated reduction in the incidence and severity of infection. Furthermore, no significant regrowth of leukaemic cells has been observed) 1,4,6] These results provide the basis for ongoing larger clinical trials of G-CSF and GM-CSF in patients with acute myeloid malignancies.
Myelodysplastic syndromes, which are characterised by a decreased proliferation and inadequate PharmacoEconomlcs 6 (Suppl. 2) 1994 maturation of haematopoietic progenitor cells, progress to acute myeloid leukaemia in up to 50% of cases.l 4 ,28] Patients with these syndromes have been the subject of some preliminary studies into the use of CSFs to ameliorate cytopenia and infection. Both G-CSF and GM-CSF have been reported to elicit a notable increase in the levels of neutrophils and their precursors, and possibly a decrease in infection rate.l 3,28] GM-CSF treatment has also resulted in increased numbers of monocytes, eosinophils, platelets and Iymphocytes.!I ] These results suggest that further studies in patients with myelodysplastic syndromes are warranted . To date, there has been no evidence of a progression to acute myeloid leukaemia as a result of CSF therapy, but the effect of long term treatment with CSFs in patients with these syndromes has yet to be studied in detail. Further clinical investigations should also determine whether certain syndromes respond better to one or other CSF.
Acquired Immune Deficiency Syndrome (AIDS)
Infection with the human immunodeficiency virus (HIV) leads to a multiplicity of cytopenias, including neutropenia, which arise from impairments in haematopoiesis. This , in turn, leaves the patient susceptible to a wide range of infections and opportunistic neoplasms. Unfortunately, this situation is complic ated by the myelosuppressive nature of antiviral, anti-infective and chemotherapeutic agents used in the treatment of AIDS and AIDS-related conditions.P''! The opportunity to alleviate viral and drug-induced neutropenia in patients with AIDS has now arisen with the introduction of CSF therapy. Preliminary data are encouraging. Treatment with G-CSF has led to significant improvements in neutrophil counts and neutrophil function, and allowed patients who were otherwise too neutropenic to receive antiviral therapy with zidovudine.l13] Furthermore, in patients receiving zidovudine, an adequate level of circulating neutrophils has been maintained by the concomitant administration of G-CSF, and in some cases patients have © Adis International Limited. All rights reserved.
Fox been able to receive additional therapy with ganciclovir. [29) Similarly, GM-CSF has been used alone to elevate neutrophil, monocyte and eosinophil counts in patients with AIDS and allowed some patients with previously severe neutropenia to receive zidovudine. GM-CSF has also been used as an adjunct to zidovudine, interferon-o; and ganciclovir therapies to maintain adequate neutrophil and monocyte counts. !6,29] It has been suggested that GM-CSF might cause an upregulation of the AIDS virus, although there is little evidence to support this, [29) and in vitro studies have suggested that GM-CSF may enhance the myelotoxicity of zidovudine by increasing zidovudine uptake into monocytes and macrophages,13] but these concerns about GM-CSF are yet to be supported or contradicted by clinical data .
3,7 Other Applications
There are several other conditions in which CSF therapy may be beneficial. These include congenital, acquired or cyclic neutropenias, radiotherapyinduced neutropenia and aplastic anaemia . Studies with G-CSF have indicated that it will have an important role to playas maintenance therapy for patients with congenital agranulocytosis and Kostmann's syndrome, as it corrects the underlying defect (a lack of mature neutrophils) by stimulating the proliferation and maturation of progenitor cells. G-CSF therapy has also reduced the severity and duration of neutropenia in patients with acquired, cyclic or idiopathic neutropenia.Fl Conversely, GM-CSF has yet to exhibit any notable clinical benefit in patients with these conditions, and resultant eosinophilia appears to be a limiting factor. These preliminary data suggest that the lineage-specific G-CSF has greater potential in the treatment of these rare disorders than GM-CSF. [2, 6] Severe aplastic anaemia is characterised by bone marrow failure and pancytopenia. Clinical studies to date suggest that patients with this disease may benefit from G-CSF or GM-CSF therapy. In patients without very severe disease, both agents have been shown to alleviate neutropenia;
GM-CSF also elevated monocyte and eosinophil counts, but had no consistent effect on platelets. However, the long term effects of treatment with these agents in patients with severe aplastic anaemia, in terms of reducing infection and sustaining myeloid cell counts, have yet to be determined. [4, 6, 13) 
Pharmacoeconomic Implications
As acquisition costs of G-CSF and GM-CSF are currently relatively high, several studies have recently addressed the pharmacoeconomic implications of using these agents for chemotherapy-induced neutropenia and to support autologous bone marrow transplantation. Data from these studies indicate that the clinical benefits of G-CSF or GM-CSF therapy, in terms of reducing the level of antibiotic use, decreasing the need for parenteral nutrition and permitting earlier discharge from hospital , lead to a reduction in overall healthcare costs . These cost savings, in general, partially or completely outweigh the costs of acquisition and administration of the drugs,l30-33) Determination of optimal dosage schedules and routes of administration in each clinical setting should help minimise the costs of treatment even further. In addition, both agents considerably improve the quality of life of patients undergoing chemotherapy or autologous bone marrow transplantation, by reducing the incidence and severity of infections and associated inpatient procedures,l30-32)
Replacing autologous bone marrow transplantation by PBPC transplantation has important pharmacoeconomic implications, as preliminary data sugge st that further reductions in the costs of hospital care can be achieved by reducing inpatient costs and the need for transfusions,l18,34j The pharmacoeconomic implications of using G-CSF and GM-CSF in other clinical settings are currently under investigation.
5..Future Prospects for Colony-Stimulating Factors
The use of CSFs has transformed the use of chemotherapy and bone marrow transplantation by facilitating haematopoietic recovery and, hence, limiting the complications asso ciated with severe neutropenia. The potential clinical uses of CSFs are many and diverse, and preliminary data in several areas show great promise. Ongoing and future clinical trials should clarify the roles of G-CSF and GM-CSF in these various clinical settings, identify which CSF is of most benefit in which situation and determine whether particular subsets of pat ients would benefit more than others from CSF treatment. Moreover, optimal dosage regimens are yet to be determined in each setting.
A major focus of all future clinical trials with these agents will be to ascertain whether the haematological and clinical advantages currently seen with CSF use will translate into a response or survival advantage in patients with nonhaematological or haematological malignancies. This is particularly true of the potential for chemotherapy dose optimisation and escalation with CSF use, as any survival advantage of dose intensification will have to be balanced against the increase in nonhaematological toxicities of intensive chemotherapy.
The pharmacoeconomic implications of using CSFs and the effects of this form of treatment on patients' quality of life will also be major contributory factors in determining the eventual clinical uses of G-CSF and GM-CSF.
The future may see the use of various combinations of CSFs and other haemopoietic growth factors in the treatment of malignant disease. Furthermore, the therapeutic potential of CSFs in patients with nonmalignant conditions, such as nonmalignant neutropenias, renal and other allografts, nonneutropenic infections and bums, has yet to be explored. In short, it is likely that the clinical utilisation of these agents will make a significant contribution to the treatment of malignancies and open many new avenues of research in relevant nonmalignant diseases.
